Stifel Financial is closing the equity research operations in its Zurich and Frankfurt offices as part of a broader European strategic retrenchment, according to reporting by Financial News London. The pullback follows the firm’s decision in late 2025 to shutter its UK equities trading business in favor of a more advisory-centric, capital-light model.
The Closure of Stifel’s Zurich and Frankfurt Research Operations
The cuts of Stifel’s Zurich and Frankfurt research teams represent the most visible sign yet of the recalibration of the firm’s European footprint. After building a pan-European research platform covering more than 400 companies through the 2019 acquisition of MainFirst, the firm is now selectively withdrawing from the research functions that made that platform distinctive. The UK equities trading closure in late 2025 preceded this move, signaling a consistent directional shift: Stifel Europe is prioritizing advisory services, corporate broking, equity research sales, and execution over capital-intensive trading and standalone research production.
No specific staff departures or timetable has been publicly confirmed for the Zurich and Frankfurt research teams. The broader strategic logic, however, is clear. Equity research in Europe has faced sustained margin pressure since MiFID II unbundling took effect in January 2018, eroding the commission economics that once cross-subsidized large continental research operations. For a mid-tier US broker-dealer operating in Frankfurt and Zurich, maintaining a full research infrastructure without a robust trading business to absorb the costs is a major disadvantage. Stifel Europe continues to operate offices in London, Frankfurt, Zurich, Geneva, Milan, Paris, and Madrid, so the retrenchment is selective rather than a wholesale exit from its business in the continent.
The 2019 MainFirst acquisition was an aggressive bet on the demand for pan-European equity coverage. Stifel rebranded MainFirst Bank AG as Stifel Europe Bank AG in November 2020, integrating the Frankfurt-based firm’s German-language corporate access network and sector research into its broader institutional offering. That build-out gave Stifel genuine depth in European mid-cap coverage. Pulling back now from two of the three German-speaking research centers suggests the economics of that expansion never fully materialized at the research level, even as the advisory and corporate broking functions retained their value.
About Stifel Financial Corp.
Stifel Financial Corp. is a St. Louis-based diversified financial services firm providing securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities. The firm operates through its principal broker-dealer subsidiaries, Stifel, Nicolaus and Company and KBW, the latter a leading investment bank focused exclusively on the financial services sector.
Stifel’s European operations are headquartered in London and Frankfurt under the Stifel Europe Bank AG entity, the successor to MainFirst Bank AG following the 2019 acquisition and the November 2020 rebrand. That acquisition gave Stifel a meaningful continental research and corporate access capability, with coverage spanning more than 400 European companies across industrials, financials, technology, and consumer sectors. The firm’s European office network spans London, Frankfurt, Zurich, Geneva, Milan, Paris, and Madrid.
The European retrenchment fits within a pattern of operational consolidation Stifel has been executing across geographies. The firm closed its Calgary office in June 2024 as part of a broader effort to concentrate resources in higher-return markets and business lines. The UK equities trading closure in late 2025 and the current Zurich and Frankfurt research cuts follow the same logic: shedding capital-intensive, lower-margin activities to redirect capacity toward advisory and investment banking, where Stifel’s client relationships and sector expertise generate better returns relative to overhead.
Whether Stifel fully exits research production in continental Europe or retains a reduced presence anchored in London remains to be seen. The firm has not publicly outlined the end state of its European research capability, and the pace of further changes over the coming months will clarify how far the retrenchment ultimately runs.
Our Take
For buy-side research heads tracking sell-side coverage trends, Stifel’s pullback from Zurich and Frankfurt is worth noting not because the firm is a dominant European research provider, but because it is a representative one. Mid-tier US broker-dealers that expanded aggressively into European research post-MiFID II, betting that unbundling would eventually create more room for independent-minded research providers, are now confronting a more difficult reality. The unbundling era compressed budgets and concentrated spending among top-tier providers, leaving firms without a dominant advisory or trading franchise struggling to justify the overhead of a full continental research operation.
The sequencing here is instructive. Stifel closed UK equities trading first, then cut Zurich and Frankfurt research. That order suggests advisory revenue is the anchor the firm is preserving, with research and trading treated as variable costs to manage around it. For institutional clients who relied on Stifel Europe’s German-language mid-cap coverage, the immediate question is whether that coverage migrates to another broker or simply disappears, adding to the coverage gap that ESMA’s issuer-sponsored research framework is specifically designed to address.
It will be interesting to watch how other US broker-dealers with subscale European research operations respond over the coming months. Stifel is unlikely to be the last firm to conclude that maintaining 400-company continental coverage without a commensurate trading book is no longer defensible.
For more news about alternative data, investment research, and investment related FinTech, click here to sign up for our free ResearchWatch Weekly newsletter, or click here to subscribe to our proprietary ResearchWatch news and commentary service.